Alnylam Pharmaceuticals (ALNY)
Health Care · RNA interference (RNAi) therapeutics
A commercial-stage RNAi therapeutics pioneer with six FDA-approved siRNA medicines targeting rare genetic and cardiometabolic diseases.
What Alnylam Pharmaceuticals does
Alnylam is a biopharmaceutical company that develops RNAi therapeutics—medicines based on small interfering RNA (siRNA) that silence disease-causing messenger RNA. The company has pioneered a proprietary platform using GalNAc conjugates and lipid nanoparticles (LNPs) for hepatic delivery and C16-based conjugates for central nervous system and ocular delivery. Alnylam has achieved regulatory approval for six first-in-class RNAi medicines: AMVUTTRA (vutrisiran) for TTR amyloidosis, ONPATTRO (patisiran) for hATTR polyneuropathy, GIVLAARI (givosiran) for acute hepatic porphyria, OXLUMO (lumasiran) for primary hyperoxaluria, Leqvio (inclisiran) for hypercholesterolemia via Novartis collaboration, and Qfitlia (fitusiran). The company is executing its Alnylam 2030 strategy, targeting TTR market leadership and expanding to over 40 clinical programs across multiple tissue types.
Themes: ["RNAi therapeutics","rare genetic diseases","transthyretin (TTR) amyloidosis","cardiology/cardiomyopathy","hepatic porphyria","metabolic disorders","precision medicine","orphan drugs","siRNA platform","gene silencing"]
Fundamentals
- Price$312.79 as of 2026-07-09 close
- Market cap$43.2B as of 2026-07-10
- 1-year return-2.5% as of 2026-07-09 close
- P/E74.83 as of 2026-07-10
- Net margin+13.5% as of 2026-07-10
- Gross margin+80.8% as of 2026-07-10
- ROE+98.3% as of 2026-07-10
- Debt / equity2.52 as of 2026-07-10
- Revenue growth (YoY)+82.6% as of 2026-07-10
- Revenue CAGR (3y)+53.0% SEC XBRL
- Beta0.24 as of 2026-07-10
Key risks (from latest filing)
["Regulatory and clinical execution risk: Success depends on approvals for next-generation products (nucresiran) and 40+ pipeline programs across multiple indications and tissue types.","Competition and market adoption: RNAi platform faces competition from gene therapy, antisense oligonucleotides, and other modalities; market adoption of existing approved medicines remains critical to revenue growth targets.","Reliance on collaborations: Two of six approved products (Leqvio, Qfitlia) are commercialized by collaborators; changes in partnership terms or partner performance could impact revenue and strategic goals."]
Competitors & peers
- Ionis Pharmaceuticals
- Moderna (mRNA vaccines and therapeutics)
- Roche/Genentech
- Novartis (collaborator on Leqvio, competitor in broader rare disease)
- Regeneron Pharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.